Home/
The Pharmaceutical Project/
Publications

Publications

Results of a first-in-human trial of LIB-01, a novel, first in class potential oral erectile dysfunction drug with unique pharmacodynamic properties. Presentation ESSM February 2025.

Results of a first-in-human trial of LIB-01, a novel, first in class potential oral ED drug with unique pharmacodynamic properties. Presentation SMSNA October 2024.

Results of a first-in-human trial of LIB-01, a novel, first in class potential oral ED drug with unique pharmacodynamic properties. Abstract SMSNA 2024.

Overview of nonclinical studies of LIB-01, a novel promising oral drug under development for treatment of erectile dysfunction. SMSNA November 2023.

The pro-erectile facilitator effect of LIB-01 in anesthesized Wistar rats is likely mediated via an NO/cGMP-independent pathway. ESSM February 2023.

Pro-erectile facilitator effect of LIB-01 in type 2 diabetic rats. October 2021.

Prolonged pro-erectile facilitator effect of LIB-01 in anesthetized Wistar rats. August 2021.

Libiguins A and B: novel phragmalin limonoids isolated from Neobeguea mahafalensis causing profound enhancement of sexual activity. DOI: 10.1055/s-0033-1360390

Semisynthesis of libiguin A and its analogues by trans-lactonization of phragmalin. DOI: 10.1021/jo500318w